Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.

Also called NCT01070030

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 230 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01070030
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01070030. Non-randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
Acronym
ACADEMY
Condition
Stage II Hypertension
Intervention (Drug)
Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01070030
Content hash
553f640122c757309f3d884877905b20dc28510b5f1a0e709fc0d155cf47a0a6